Efficacy of Albumin-Bound Paclitaxel Combined With Radiotherapy in Non-Small Cell Lung Cancer With Superior Vena Cava Syndrome
Objective To analyze the efficacy of albumin-bound paclitaxel combined with radiotherapy for non-small cell lung cancer (NSCLC) with superior vena cava syndrome (SVCS). Methods The clinical data of 28 patients with NSCLC with SVCS treated with albumin-bound paclitaxel combined with radiotherapy during the same period in the Eighth Affiliated Hospital of Guangxi Medical University from January 2019 to January 2022 were retrospectively analyzed. Recent efficacy,survival time and adverse effects of 28 patients were analyzed. Results Among 28 patients with NSCLC and SVCS,the objective response rate (ORR) was 71.43％,disease control rate (DCR) was 89.29％,median progression-free survival time was 3.30 months (95％CI 2.56 to 4.04 months) and median survival time was 7.20 months (95％CI 6.44 to 7.98 months). The number of chemotherapy lines and T stage are independent risk factors affecting progression-free survival (PFS) (P<0.05). The number of chemotherapy lines and N stage are independent risk factors affecting overall survival (OS) (P<0.05). Adverse reactions include hematologic reaction,gastrointestinal,joint and peripheral neurotoxicity,hepatic and renal function impairment and acute radiation reaction. Conclusion Albumin-bound paclitaxel combined with radiotherapy has good objective efficacy and safety in patients with NSCLC with SVCS;patients with T stage≤3 and N stage<2 may benefit more from treatment.
superior vena cava syndromeradiotherapyalbumin-bound paclitaxelchemotherapylung cancerconcurrent radiotherapy
万方数据
维普
